Comparison between immune response to different modes of vaccination: intradermal and subcutaneous yellow fever vaccination

Submission date	Recruitment status No longer recruiting	Prospectively registered		
20/12/2005		☐ Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
20/12/2005		[X] Results		
Last Edited	Condition category	Individual participant data		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr A.H.E. Roukens

Contact details

Leiden University Medical Centre (LUMC) Albinusdreef 2, C5-P Leiden Netherlands 2333 ZA

a.h.e.roukens@lumc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Comparison between immune response to different modes of vaccination: intradermal and subcutaneous yellow fever vaccination

Study objectives

Intradermal yellow fever vaccination with a reduced dose will induce a sufficient protective immunological response comparable to the response elicited by subcutaneous yellow fever vaccination.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Yellow Fever

Interventions

Subcutaneous of intradermal yellow fever vaccination.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Yellow fever vaccination

Primary outcome measure

- 1. Protective humoral immune response
- 2. For first time vaccinees measured 4 and 8 weeks post-vaccination, for revaccinees measured 2 weeks post-vaccination.
- 3. All sera will be analysed by ELISA, Immunofluorescence and plaque reduction assay.

Secondary outcome measures

Adverse events measured for three weeks post-vaccination by keeping a diary, viremia measured 5 days post-vaccination by RT-PCR.

Overall study start date

15/06/2005

Completion date

15/06/2006

Eligibility

Key inclusion criteria

Healthy volunteers, greater than 18 years (previously and not previously vaccinated with yellow fever vaccine)

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

120

Total final enrolment

155

Key exclusion criteria

- 1. Pregnancy
- 2. Diabetes mellitus
- 3. Use of immunomodulating medication, e.g. corticosteroids
- 4. Cytostatica
- 5. Use of chloroquine

Date of first enrolment

15/06/2005

Date of final enrolment

15/06/2006

Locations

Countries of recruitment

Netherlands

Study participating centre Leiden University Medical Centre (LUMC) Leiden Netherlands 2333 ZA

Sponsor information

Organisation

Leiden University Medical Centre (LUMC) (Netherlands)

Sponsor details

Albinusdreef 2 P.O. Box 9600 Leiden Netherlands 2300 RC

Sponsor type

University/education

Website

http://www.lumc.nl/

ROR

https://ror.org/027bh9e22

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Leiden University Medical Centre (LUMC) (The Netherlands) - Department of Infectious Diseases

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	23/04/2008		Yes	No
Results article	results	04/12/2018	02/09/2019	Yes	No